Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non -diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial

by Cherney, David Z., Dekkers, Claire C. J., Barbour, Sean J., Cattran, Daniel, Gafor, Abdul Halim Abdul, Greasley, Peter J., Laverman, Gozewijn D., Lim, Soo Kun, Di Tanna, Gian Luca, Reich, Heather N., Vervloet, Marc G., Wong, Muh Geot, Gansevoort, Ron T., Heerspink, Hiddo J. L., Investigators, DIAMOND
Published 2020

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

by van der Aart-van der Beek, Annemarie B., Koomen, Jeroen V., Dekkers, Claire C.J., Barbour, Sean J., Boulton, David W., Gansevoort, Ron T., Greasley, Peter J., Abdul Gafor, Abdul Halim, Laverman, Gozewijn D., Li, Qiang, Lim, Soo Kun, Stevens, Jasper, Vervloet, Marc G., Singh, Sunita, Cattran, Daniel C., Reich, Heather N., Cherney, David Z.I., Heerspink, Hiddo J.L.
Published 2021

Evaluation of the pharmacokinetics and exposure-response relationship of dapagliflozin in patients without diabetes and with chronic kidney disease

by van der van der Beek, Annemarie B., Koomen, Jeroen V., Dekkers, Claire C. J., Barbour, Sean J., Boulton, David W., Gansevoort, Ron T., Greasley, Peter J., Abdul Gafor, Abdul Halim, Laverman, Gozewijn D., Li, Qiang, Lim, Soo Kun, Stevens, Jasper, Vervloet, Marc G., Singh, Sunita, Cattran, Daniel C., Reich, Heather N., Cherney, David Z. I., Heerspink, Hiddo J. L.
Published 2021